Medical Program: Special Considerations in NSCLC: Treating PD-L1 High Patients

Special Considerations in NSCLC: Treating PD-L1 High Patients

Special Considerations in NSCLC: Treating PD-L1 High Patients
RestartResume

Since PD-L1 expressions can be seen in about 30 percent of non-small cell lung cancer patients, knowing how to treat these patients is critical.

  • Overview

    Testing for the biomarker PD-L1 can offer clinicians direction for their treatment approach to non-small cell lung cancer, and here to offer insights on therapeutic approaches for patients with high PD-L1 expression is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida. 

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free